Loading clinical trials...

ACTIVE_NOT_RECRUITING

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

NCT04263181•Washington University School of Medicine

Summary

In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
•Peripheral blood blasts \> 1%
•Peripheral white blood cell count \> 1,000/µl.
•Age ≥ 18 years
•Anticipated treatment with any of the following regimens (Cohort 0) or:
•* Cohort 1: A standard induction protocol with infusional cytarabine
•* Cohort 2: Decitabine (either 5-day or 10-day regimens)
•* Cohort 3: Azacitidine (either intravenous or subcutaneous administration)
•* Cohort 4: Decitabine (either 5-day or 10-day) + venetoclax
•* Cohort 5: Azacitidine (either intravenous or subcutaneous administration on 7 day or 5+2+2 schedule) + venetoclax
+5 more criteria

Exclusion Criteria

•Pregnant or currently nursing
•Prior chemotherapy with hypomethylating agents
•Known history of positive HIV serology.
•Known positive Hepatitis C serology.

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

January 29, 2020

Primary Completion Date

January 31, 2027

Completion Date

January 31, 2027

Last Updated

March 2, 2026

Enrollment

ACTUAL participants

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

Peripheral blood draw

PROCEDURE

Bone marrow aspirate

PROCEDURE

Buccal swab

PROCEDURE

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

NCT06220162

Acute Myeloid Leukemia

View study

RECRUITINGPHASE1/PHASE2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Inclusion Criteria

Exclusion Criteria

Phase I Study of HC-7366 for Acute Myeloid Leukemia

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes